MedTrace Logo

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

NCT00879554 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-12-13

No results posted yet for this study

Summary

The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

CVX-045

Weekly, intravenous dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-03-31
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00879554 on ClinicalTrials.gov